Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety evaluation of Zedoary Turmeric Oil Injection
ChiCTR2200064482Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Aug 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zedoary turmeric oil in bronchopulmonary diseases, Infectious disease and childhood disease, sponsored by Beijing University of Chinese Medicine. Primary endpoints: Adverse drug reactions and Adverse events. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
zedoary turmeric oil
03
Conditions
bronchopulmonary diseasesInfectious diseasechildhood disease
Beyond the preview
Go deeper on ChiCTR2200064482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064482.